SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2013

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

NOTE 4. SEGMENT INFORMATION

We operate in one business segment: the research, development and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

Our revenues are currently derived primarily from five licensees for international activities and our domestic sales activities of Altrazeal®.

Revenues per geographic area, along with relative percentages of total revenues, for the three and six months ended June 30 are summarized as follows:

	Three Months Ended June 30,										Six Months Ended June 30,
Revenues	2013		%			2012		%			2013		%			2012		%
Domestic	$	17,610		61	%	$	46,407		83	%	$	37,397		71	%	$	98,453		85	%
International		11,274		39	%		9,804		17	%		93,531		29	%		17,763		15	%
Total	$	28,884		100	%	$	56,211		100	%	$	130,928		100	%	$	116,216		100	%

A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total sales, along with their relative percentage of all sales, for the three and six months ended June 30 are represented on the following table:

		Three Months Ended June 30,						Six Months Ended June 30,
Customers	Product	2013			2012			2013			2012
Customer A	Altrazeal®		---			---			57	%		---
Customer B	Aphthasol®		---			30	%		---			29	%
Customer C	Altrazeal®		29	%		*			*			*
Total			29	%		30	%		57	%		29	%

* Sales from this customer were less than 10% of total sales for the period reported.